“2012年中国医药产业将实现19-21%的增长。”昨日，中国医保商会副会长许铭向记者表示。不过，企业出口形势不容乐观，进行产业升级，并通过“走出去”深耕海外市场势在必行。

"In 2012, the Chinese medicine industry will achieve 19-21% growth."yesterday,China's health care, vice chairman of the chamber of commerce XuMing told reporters.but,Enterprises to export situation is not optimistic,For industrial upgrading,And through the"Go out"Subsoil overseas market is imperative.

　　据了解，今年医药产业总规模将达到1.8万亿元，行业平均利润水平在10%。其中，制药业将实现9000亿的销售规模，细分子行业中，生物医药的利润率最高，达15%；中药为11%，原料药在9.8%、化药的利润率较低。

It is understood,This year the pharmaceutical industry total scale will reach 1.8 trillion yuan,The industry average profit level of 10%.the,The pharmaceutical industry will achieve the 900 billion sales scale,Small molecule in the industry,Biological medicine highest profit margins,15%;Traditional Chinese medicine is 11%,API in 9.8%/Chemical drug profit margin is low.

　　就发展趋势而言，出口形势依然不容乐观。今年1-10月，我国医药行业出口增速为7.8%，国外市场需求在下降，欧美以往的长单变短单，新客户来源不足，导致企业各项成本迅速上升，经营风险增加。

For on the trend of development,Export situation is still not optimistic.This year October 1 -,China's pharmaceutical industry export growth was 7.8%,The foreign market demand is down,Europe and the United States before long single shorten single,The new customer source shortage,Lead to enterprise the cost rising rapidly,Increased risk management.

　　此外，许铭指出，印度对我国医药出口造成的威胁越来越大。从今年下半年来看，我国的医药工业出口已进入困难期。除小部分企业如恒瑞医药(600276,股吧)等，已完成产业升级，能实现跨周期增长，而大多数未做好准备的企业，遭遇的困难或比2009年更大。

In addition,XuMing pointed out that,India to our country medicine export the threat of more and more big.From the second half of this year to see,China's pharmaceutical industry has entered the export business.Apart from a small proportion of enterprise such as HengRui medicine(600276,guba)etc,Has completed industrial upgrading,Can realize span cycle growth,While most not ready to enterprise,The difficulties or more than 2009 years.

　　值得关注的是，面对行业发展的低潮期，更多更有实力的企业把目光瞄准了海外市场。据许铭统计，截至目前，已有40多家中国医药企业在美国投资涉厂。在美国部分地区，对外资医药企业在药品审批、市场准入方面有优惠条件。因此，如恒瑞、海正、华海、包括天士力(600535,股吧)等医药企业，都纷纷在美国当地投资，建设厂房，开拓市场。“如迈瑞医疗，该公司的产品甚至已经进入了美国当地的政府采购目录。”许铭这样告诉记者。

There is concern,With the development of the industry -,More powerful enterprise look aimed at the overseas market.According to XuMing statistics,So far,For more than forty home China pharmaceutical enterprise in the United States investment in factory.In parts of the United States,For foreign pharmaceutical enterprises in the drug approval/Market access conditions are favorable.so,If HengRui/The sea is/huahai/Including TianShiLi(600535,guba)Pharmaceutical enterprise such as,In the United States have local investment,building,Develops the market."Such as mindray medical,The company's products and even have entered the American local government procurement catalogue."XuMing told reporters.

　　许铭认为，我国的原料药出口已居世界第一位，但从今年的情况来看，以往的维生素C、E的出口额都在下降，企业利润情况开始缩水，部分都已经亏损。未来，特色原料药、包括制剂的出口正方兴未艾，中国医药产业必须完成结构调整和产业升级，才能在竞争激烈的海外市场上，在越来越严苛的欧美监管体制下，拓宽出口之路。

XuMing think,China's export API is the highest in the world first,But from this year's situation,Previous vitamin C/E exports are falling,Enterprise profit condition began to shrink,Parts have been losses.The future,Characteristic API/Including the export of preparation in the ascendant,Chinese medicine industry must complete structure adjustment and industrial upgrading,Can in the fierce competition in the overseas market,More and more severe in Europe and the United States regulatory system,Broaden the export road.

　　如以华海药业为例，2007年6月25日，华海药业收到了来自美国FDA官方的函件，确认华海的抗艾滋病药奈韦拉平制剂产品以及生产线以零缺陷通过了美国FDA认证。其实，华海美国子公司早在2004年10月就在“美国药谷”之称的新泽西州注册成立。“在众多制药企业中，华海能够领先一步获得美国FDA认证，依靠的是管理理念、设备条件、质量意识，而最重要的是人才。”华海药业董事长兼总经理陈保华这样向记者表示。

Such as to huahai pharmaceutical industry as an example,June 25, 2007,Huahai pharmaceutical received from American FDA official correspondence,Confirm the huahai AIDS drug nevirapine preparation products and production line to zero defect through the American FDA certificate.In fact,Huahai us subsidiary early in October 2004 in"The United States YaoGu"New Jersey, was registered."In many pharmaceutical enterprises,Huahai ahead to get American FDA certificate,Is relying on the management concept/Equipment condition/Quality consciousness,But the most important thing is the talent."Huahai pharmaceutical chairman and general manager ChenBaoHua such told reporters.